Siddhant U Jain
Overview
Explore the profile of Siddhant U Jain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
986
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jain S, Khazaei S, Marchione D, Lundgren S, Wang X, Weinberg D, et al.
Proc Natl Acad Sci U S A
. 2020 Oct;
117(44):27354-27364.
PMID: 33067396
A high percentage of pediatric gliomas and bone tumors reportedly harbor missense mutations at glycine 34 in genes encoding histone variant H3.3. We find that these H3.3 G34 mutations directly...
2.
Jain S, Rashoff A, Krabbenhoft S, Hoelper D, Do T, Gibson T, et al.
Mol Cell
. 2020 Oct;
80(4):726-735.e7.
PMID: 33049227
Diffuse midline gliomas and posterior fossa type A ependymomas contain the recurrent histone H3 lysine 27 (H3 K27M) mutation and express the H3 K27M-mimic EZHIP (CXorf67), respectively. H3 K27M and...
3.
Khazaei S, De Jay N, Deshmukh S, Hendrikse L, Jawhar W, Chen C, et al.
Cancer Discov
. 2020 Sep;
10(12):1968-1987.
PMID: 32967858
Glycine 34-to-tryptophan (G34W) substitutions in H3.3 arise in approximately 90% of giant cell tumor of bone (GCT). Here, we show H3.3 G34W is necessary for tumor formation. By profiling the...
4.
Jain S, Do T, Lund P, Rashoff A, Diehl K, Cieslik M, et al.
Nat Commun
. 2019 May;
10(1):2146.
PMID: 31086175
Posterior fossa type A (PFA) ependymomas exhibit very low H3K27 methylation and express high levels of EZHIP (Enhancer of Zeste Homologs Inhibitory Protein, also termed CXORF67). Here we find that...
5.
Jani K, Jain S, Ge E, Diehl K, Lundgren S, Muller M, et al.
Proc Natl Acad Sci U S A
. 2019 Apr;
116(17):8295-8300.
PMID: 30967505
Enhancer of Zeste Homolog (EZH2) is the catalytic subunit of Polycomb Repressor Complex 2 (PRC2), the enzyme that catalyzes monomethylation, dimethylation, and trimethylation of lysine 27 on histone H3 (H3K27)....
6.
Harutyunyan A, Krug B, Chen H, Papillon-Cavanagh S, Zeinieh M, De Jay N, et al.
Nat Commun
. 2019 Mar;
10(1):1262.
PMID: 30890717
Lys-27-Met mutations in histone 3 genes (H3K27M) characterize a subgroup of deadly gliomas and decrease genome-wide H3K27 trimethylation. Here we use primary H3K27M tumor lines and isogenic CRISPR-edited controls to...
7.
McDaniel S, Gibson T, Schulz K, Garcia M, Nevil M, Jain S, et al.
Mol Cell
. 2019 Feb;
74(1):185-195.e4.
PMID: 30797686
Reprogramming cell fate during the first stages of embryogenesis requires that transcriptional activators gain access to the genome and remodel the zygotic transcriptome. Nonetheless, it is not clear whether the...
8.
Bayliss J, Mukherjee P, Lu C, Jain S, Chung C, Martinez D, et al.
Sci Transl Med
. 2016 Nov;
8(366):366ra161.
PMID: 27881822
Childhood posterior fossa (PF) ependymomas cause substantial morbidity and mortality. These tumors lack recurrent genetic mutations, but a subset of these ependymomas exhibits CpG island (CpGi) hypermethylation [PF group A...
9.
Jayaram H, Hoelper D, Jain S, Cantone N, Lundgren S, Poy F, et al.
Proc Natl Acad Sci U S A
. 2016 May;
113(22):6182-7.
PMID: 27185940
Lysine to methionine (K-to-M) mutations in genes encoding histone H3 are thought to drive a subset of pediatric brain and bone cancers. These high-frequency K-to-M mutations occur at sites of...
10.
Lu C, Jain S, Hoelper D, Bechet D, Molden R, Ran L, et al.
Science
. 2016 May;
352(6287):844-9.
PMID: 27174990
Several types of pediatric cancers reportedly contain high-frequency missense mutations in histone H3, yet the underlying oncogenic mechanism remains poorly characterized. Here we report that the H3 lysine 36-to-methionine (H3K36M)...